罗氏Roche Holdings（RHHBY）2016年年度报告「OTC」.pdf

1、Who we areInnovation:Its in our DNA.We have always worked across disciplines and geographies to drive scientific discovery and redefine what is possible to improve patients lives.We are working on understanding how diseases differ down to the molecular level.So we can developnew tests and medicines

2、that prevent,diagnose and treat diseases,and bring them to the patients who need them.With our combined strengthsin diagnostics and pharmaceuticals,our personalised healthcare strategy aims to fit the righttreatment to the right patient.As the worlds largest biotech company,we develop breakthrough m

3、edicines,improving the standard of care across oncology,immunology,infectious diseases,ophthalmology and neuroscience.We are also the world leader in the in vitro diagnostics business.This track record allows us to build lasting and meaningful partnerships across the world with research academia and

4、 public healthcare institutions.The founding families continue to hold the majority voting stake in the company.This stability allows for a tradition of sustainable thinking,so we can learn from setbacks and focus on lasting value for patients and society.We remain dedicated to the highest standards

5、 of quality,safety and integrity.Our legacy is based on respect for the individual as well as the communities and the world we live in.Annual Report 2016P A T I E N T S We recently launched four new cancer treatments,with our first cancer immunotherapy medicine Tecentriq giving new hope to people wi

6、th specific types of bladder and lung cancer.I N N O V A T I O N We were granted five breakthrough therapy designations by the US Food and Drug Administration forour medicines,and added nine key diagnostic instruments and tests to our rich portfolio.P A R T N E R STogether with our partners,we made